Elaine Moore writes,
With the increasing costs of specialized drugs, some insurance companies are refusing to pay for drugs prescribed for off-label conditions …
Health policy analysts caution that the benefits off-label drugs offer in conditions for which other drugs have failed will be seriously compromised by these new insurance regulations.
Furthermore, off-label drugs such as naltrexone, which [...]

[Read more →]